COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00694148
Recruitment Status : Completed
First Posted : June 10, 2008
Last Update Posted : October 30, 2012
Information provided by (Responsible Party):
Merz Pharmaceuticals GmbH

Brief Summary:
NT 201 is a Botulinum toxin type A preparation free of complexing proteins. Injected into the muscle, NT 201 causes a reversible local relaxation of the injected muscle. Botulinum toxin type A is widely used for aesthetic treatment of mimic wrinkles. This study will investigate the safety and efficacy of NT 201 in the treatment of glabellar frown lines.

Condition or disease Intervention/treatment Phase
Healthy Drug: NT 201 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 108 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: NT 201 is a Botulinum Toxin Type A Preparation Free of Complexing Proteins. Injected Into the Muscle, NT 201 Causes a Reversible Local Relaxation of the Injected Muscle. Botulinum Toxin Type A is Widely Used for Aesthetic Treatment of Mimic Wrinkles. This Study Will Investigate the Safety and Efficacy of NT 201 in the Treatment of Glabellar Frown Lines.
Study Start Date : May 2008
Actual Primary Completion Date : January 2009
Actual Study Completion Date : January 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Botox

Intervention Details:
  • Drug: NT 201

    A Botulinum neurotoxin type A, free of complexing proteins

    Detailed described in study protocol

Primary Outcome Measures :
  1. Investigator`s assessment [ Time Frame: 4 weeks after initial injection session ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • moderate to severe glabellar frown lines at maximum frown ((severity score of 2 or 3 on Facial Wrinkle Scale(FWS)as assessed by the investigator's rating: 0 = 'none', 1 = 'mild', 2 = 'moderate', 3 = 'severe'
  • Stable medical condition
  • Age: between 18 and 65 years (inclusively)

Exclusion Criteria:

  • Previous treatment with Botulinum toxin of any serotype in the upper third part of the face within the last 6 month
  • Previous treatment with biodegradable fillers in the glabellar area within the last 12 month
  • Previous insertion of permanent material in the glabellar area, including fat graft (regardless of the time between previous treatment and this study)
  • Any surgery in the glabellar area including surgical removal of the corrugator, procerus, or depressor supercilii muscles or a combination of these, or scars in the glabellar area
  • Any other planned cosmetic procedure in the upper third part of the face during the trial period
  • Inability to substantially lessen glabellar frown lines even by physically spreading them apart
  • Marked facial asymmetry or ptosis of eyelid and/or eyebrow
  • History of facial nerve palsy
  • Any infection in the area of the injection sites

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00694148

Layout table for location information
Dr. Matthias Imhof, Medico Palais Bad Soden
Bad Soden, Hessen, Germany, 65812
Sponsors and Collaborators
Merz Pharmaceuticals GmbH
Layout table for investigator information
Principal Investigator: Matthias Imhof, MD Ästhetische Dermatologie, Medico Palais Bad Soden

Publications of Results:
Layout table for additonal information
Responsible Party: Merz Pharmaceuticals GmbH Identifier: NCT00694148    
Other Study ID Numbers: MRZ 60201 GL_3001
2008-000549-73 ( EudraCT Number )
First Posted: June 10, 2008    Key Record Dates
Last Update Posted: October 30, 2012
Last Verified: October 2012
Keywords provided by Merz Pharmaceuticals GmbH:
Treatment of glabellar frown lines
Additional relevant MeSH terms:
Layout table for MeSH terms
Botulinum Toxins
Botulinum Toxins, Type A
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents